Spektus Pharma and Gebro Holding launch global commercialization partnership for ActraFlex

What happened: Spektus PharmaDealroom has a profile for this one. Try Dealroom → (Laval, Canada) and Gebro Holding GmbHDealroom has a profile for this one. Try Dealroom → (Fieberbrunn, Austria) announced on 3 November 2026 a strategic global commercialization partnership for ActraFlex, a novel twice-daily extended-release formulation combining tramadol and paracetamol for pain management. Under the agreement, the companies will divide global commercialization responsibilities across key international markets.

Why it matters: ActraFlex pairs two well-established analgesics — an opioid and a non-opioid painkiller — in a prolonged-release format designed for round-the-clock pain control with twice-daily dosing. The partnership pairs Spektus's development capability with Gebro, an established European pharmaceutical group, to take the product to market across multiple regions, and extends Gebro's product portfolio beyond its home-market brands.

Read more: Spektus Pharma via CNW, 3 November 2026